Anthony Azzi, MD
Internal Medicine · Raleigh, NCNPI 1447228283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,425 of the $81,371 with a category attached, or 80.4%. AstraZeneca accounts for 63.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $43,520 and has fallen 99.7% since, to $128 in 2023. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $274.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$52K
- Mannkind Corporation$22K
- Insulet Corporation$5K
- Medtronic$279
- Novo Nordisk$270
- Amgen$201
- plus $1K from 26 others
What the payments were for
- Consulting fees$6,1838%
- Speaking & faculty fees$65,42580%
- Travel & lodging$4,7356%
- Food & beverage$4,8996%
- Education$700%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $52,016 |
| Mannkind Corporation | 67 | $22,104 |
| Insulet Corporation | 17 | $5,226 |
| Medtronic(2 entities) | 18 | $279 |
| Novo Nordisk | 21 | $270 |
| Amgen | 16 | $201 |
| Amarin Pharma, Inc. | 9 | $167 |
| Zealand Pharma US, Inc. | 2 | $164 |
| Johnson & Johnson | 19 | $113 |
| Sanofi-aventis U.S. LLC | 7 | $97 |
| Esperion Therapeutics, Inc. | 1 | $97 |
| Lilly USA, LLC | 6 | $79 |
| Abbott | 4 | $68 |
| Corcept Therapeutics | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Boehringer Ingelheim | 3 | $46 |
| Dexcom, Inc. | 3 | $44 |
| Tandem Diabetes Care, Inc. | 3 | $37 |
| Radius Health, Inc. | 2 | $36 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| Companion Medical, Inc. | 2 | $26 |
| AbbVie | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Vivus LLC | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,371 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Raleigh
- Bhakti PaulRaleigh$536K
- Christina CraterRaleigh$330K
- Charles CookRaleigh$228K
- Dishita PandyaRaleigh$71K
- Afreen ShariffRaleigh$66K
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.